RecruitingNCT07030400
Predictors of Health-Related QOL in Adults With CLL or Small Lymphocytic Lymphoma
Predictors of Health-Related Quality of Life in Adults With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Enrollment
100 participants
Start Date
Jul 17, 2025
Study Type
OBSERVATIONAL
Conditions
Summary
The study aims to improve our understanding of how quality of life, fatigue, and symptoms change over 2 years when participants are treated for chronic lymphocytic leukemia or small lymphocytic lymphoma. We will compare two types of treatment to help future patients with chronic lymphocytic leukemia or small lymphocytic lymphoma know what to anticipate.
Eligibility
Min Age: 18 Years
Inclusion Criteria2
- All patients with pathology-confirmed diagnoses of CLL who are within seven days of starting treatment with a BTKi +/- an anti-CD 20 monoclonal antibody or BCL2i with Obinutuzumab treatment will be included.
- Subjects must be able to read and speak English or Spanish at the 8th grade level.
Exclusion Criteria1
- Patients with dementia, traumatic brain injury, or individuals with central nervous system involvement of their leukemia will be excluded from study participation.
Interventions
DRUGBruton's tyrosine kinase inhibitor
BTKi
DRUGB-Cell Lymphoma 2 Protein Inhibitor
BCL2i
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07030400
Related Trials
Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)
NCT038244838 locations
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
NCT0513102262 locations
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
NCT0722150018 locations
Immune Profiling of CLL/SLL Treated With First-Line Pirtobrutinib
NCT074287071 location
Observational Study of Acalabrutinib in Patients With Chronic Lymphocytic Leukaemia in the United Kingdom
NCT0555769529 locations